Immunovant (IMVT) Stock Statistics & Valuation Metrics

Immunovant has a market cap or net worth of $7.96B. The enterprise value is $6.22B.

Immunovant has 205,308,910 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immunovant’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -62.46%.

The current PE Ratio of Immunovant is ―. Immunovant’s PEG ratio is -6.12.

In the last 12 months, Immunovant had revenue of 0.00 and earned -505.61M in profits. Earnings per share was -2.77.

In the last 12 months, operating cash flow was -407.31M and capital expenditures -8.00K, giving a free cash flow of -407.32M billion.

Immunovant pays an annual dividend of ―, resulting in a dividend yield of ―

Immunovant upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).

Immunovant as a current ratio of 9.09, with Debt / Equity ratio of <0.01%

In the past 12 months, Immunovant has paid 215.00K in taxes.

Immunovant EV to EBITDA ratio is -7.19, with an EV/FCF ratio of -8.91.

Immunovant has $902.11M in cash and marketable securities with $72.00K in debt, giving a net cash position of $902.04M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Immunovant is $47.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy